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Summary: The effect of sodium valproate (200 mg/kg body weight) on renal cells was investigated during a 10-
day trial, by determining the catalytic activities of alanine aminopeptidase, γ-glutamyltransferase and alkaline
phosphatase in the membrane cell brush-border of the renal proximal tubules.
Four days after the administration of sodium valproate, a significant increase was observed in the volume of
urine (9.2 ± 4.2 ml/18-h volume; control group, 3.06 ± 1.8 ml/18-h volume), and in the catalytic activities of γ-
glutamyltransferase (2.69 times that measured in the control group) and alkaline phosphatase (3.02 times that
measured in the control group) in urine. After prolonged treatment the urine became alkaline (pH = 10.5 on day 10),
thereby excluding alanine aminopeptidase as a useful indicator of renal cell changes following the administration
of sodium valproate. The activities of alkaline phosphatase and γ-glutamyltransferase in isolated vesicles of renal
brush-border membrane cells were significantly increased (p < 0.05) and decreased, respectively.
On the basis of the results obtained, we believe that the determination of the catalytic activities of γ-glutamyltrans-
ferase and alkaline phosphatase in urine might prove useful for the follow-up of the renal cell state during therapy
with sodium valproate.
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Materials and Methods
Material
The study was performed on male Fisher rats (n = 29) aged 1
month, mean body weight 100g. The animals had free access to
chow and water throughout the study. The animals were divided
into four groups: the control group (n = 6) received 1 ml saline
(0.154 mol/1 NaCl) daily per os. The experimental group (n = 23)
received 200 mg/kg body weight sodium valproate daily per os in
the same volume. Experimental animals were sacrificed by sever-
ing the cranial spine on day 1 (n = 8), day 4 (n = 7) and day
10 (n = 8).
Prior to sacrifice, the 18-h urine was collected in metabolic cages
for each group of animals. Urine volume and pH were readily de-
termined by test strips. Urine was tested for the presence of protein,
glucose, haemoglobin and ketone bodies, and centrifuged at 1500
min"' for 10 min in a Tehnica LC 320 laboratory centrifuge. Dialy-
sis (PM exclusion 12000-14000), PolyLabo, Strasbourg, France)
was performed against water for 3 h to remove possible enzyme
inhibitors. Catalytic activities of the enzymes were then readily
determined in the dialysed urine samples.
After sacrificing animals under ether narcosis on day 1, 4 and 10,
blood was withdrawn from the umbilical vein. Blood serum was
separated by centrifugation at 3000 min"·1 for 10 min and serum
urea concentration was determined.
Immediately after sacrifice, the kidneys were excised, washed in
cold saline, dried with filter paper and freed from the connective
tissue and capsules.
Renal cortex sections prepared with a microtome were minced,
placed in 15ml buffer (Tris-HCl, 12 mmol/1, pH = 7.4; EGTA,
5 mmol/1; mannitol, 300 mmol/1), then homogenized with an Ultra
Turrax homogenizer, type 18-10 (Janke & Kunkel, GK). Brush
border membrane vesicles were isolated by precipitation with Mg
ions, according to Biber et al. (14), using a Beckman L5-65 ultra-
centrifuge. Protein concentration and catalytic activities of alanine
aminopeptidase, alkaline phosphatase and γ-glutamyltransferase
were determined in isolated brush-border membrane vesicles.
Mean values of the factor of enzymatic activity enrichment,
following brush border membrane vesicle isolation, were f = 11.0,
f = 8.0 and f = 10.0 for alanine aminopeptidase, alkaline phospha-
tase and γ-glutamyltransferase, respectively.
Methods
The catalytic activity of alanine aminopeptidase was determined
by the procedure of Haschen (15) on a Pye Unicam SP-6-550 UV/
VIS spectrophotometer, that of alkaline phosphatase by the pro-
cedure of McComb & Bowers (16), and that of γ-glutamyltransfer-
ase by the procedure of Szasz et al. (17) on a Centrifichem 400
autoanalyser. Serum urea concentration was determined by the
method of Sampson et al. (18) on a Centrifichem 400 autoanalyser.
The protein concentration of isolated brusteborder membrane
vesicle preparations was determined by the procedure of Bradford
et al. (19) on a Pye Unicam SP-6-550 UV/VIS spectrophotometer.
Chemicals
Commercial test kits for alkaline phosphatase, γ-glutamyltransfer-
ase and urea were obtained from Herbos, Sisak, manufactured in
cooperation with SKI (Smith & Kline Instruments, Inc. USA).
EGTA, Fluka; HEPES and DL-alanine- -naphthylamide · HC1,
Sigma; and all other chemicals of analytical purity were obtained
from Kemika, Zagreb.
The statistical significance of changes in enzyme catalytic activities
in the experimental group samples, compared with those in control
animals, were analysed by Student's t test for small samples (20).
Results
Prior to the determination of enzyme catalytic activities
in the samples, an in vitro experiment performed on pool
serum showed that sodium valproate caused no signifi-
cant interference in the determination of alanine amino-
peptidase, alkaline phosphatase and γ-glutamyltransfer-
ase catalytic activities.
A routine urine analysis was performed to test kidney
function. Protein, glucose, ketone bodies and haemoglo-
bin appeared to be normal in all groups of animals.
Moreover, the concentration of urea in serum as well
as the concentration of protein in kidney brush border
membrane vesicles did not change throughout the ex-
periment.
After four days of sodium valproate administration, the
18-h urine volume was significantly increased (9.2
± 4.2 ml) in comparison with the control group (3.06
± 1.8 ml) (p < 0.05); urine pH was markedly increased
to 10.5 after 10 days of sodium valproate administration
(control group, pH = 6.0) (tab. 1).
Changes in the enzyme catalytic activities in 18-h urine
samples and isolated renal brush-border membrane
vesicles are shown in figures 1, 2 and 3. On day 1 of the
administration of sodium valproate, only the catalytic
activity of alanine aminopeptidase in urine was
increased significantly (2.0 times that found in the con-
trol group; p < 0.05) (fig. 1). The enzyme activity grad-
ually decreased, attaining control group values on day
10. In isolated renal brush-border membrane vesicles,
the alanine aminopeptidase activity showed a significant
change only on day 1 of the experiment.
The catalytic activities of γ-glutamyltransferase and al-
kaline phosphatase in the urine of experimental animals
were significantly increased on day 4 of sodium val-
proate administration (γ-glutamyltransferase, 2.69-fold,
p < 0.05; alkaline phosphatase, 3.02-fold, ρ < 0.001)
(figs. 2 and 3). On day 10 of the treatment, the catalytic
activity of γ-glutamyltransferase in urine was within the
control group values, whereas the catalytic activity of
alkaline phosphatase was below the control group value.
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Fig. 1 Effect of sodium valproate on the catalytic activity of ala-
nine aminopeptidase in rat urine and kidney brush border mem-
brane vesicles. Changes in enzyme catalytic activity are presented
as relative activities in comparison to control group values.
Control group activities in urine (D—Π) and kidney brush border
membrane vesicles (O-O) were: 0.036 ± 0.01 U/18 h volume and
299.5 ± 55 U/mg protein, respectively; *p < 0.05
10 t[d]
Fig. 3 Effect of sodium valproate on the catalytic activity of alka-
line phosphatase in rat urine an kidney brush border membrane
vesicles. Changes in enzyme catalytic activity are presented as rela-
tive activities in comparison to control group values.
Control group activities in urine (Π-α) and kidney brush border
membrane vesicles (O-O) were: 0.10 ± 0.06 U/18 h volume and
2485 ± 178 U/mg protein, respectively; *p < 0.05; **p <0.01
1 10 t[d]
Fig. 2 Effect of sodium valproate on the catalytic activity of γ-
glutamyltransferase in rat urine an kidney brush border membrane
vesicles. Changes in enzyme catalytic activity are presented as rela-
tive activities in comparison to control group values.
Control group activities in urine (B-D) and kidney brush border
membrane vesicles (o-^O) were: 0.685 ±0.13 U/l£ h volume and
12955 ± 2142 U/mg protein, respectively; *p < 0.05
The activity of y^glutamyltransferase in isolated renal
brush-border membrane vesicles was,decreased about
0.30-, 0.40- and 0.18-fold on days 1, 4 and 10, respec-
tively, whereas the activity of alkaline phosphatase was
significantly increased (from 1.45-fold on days 1 and 4
to 2.18-fold on day 10 of the trial; p < 0.05).
Discussion
A relatively small number of adverse effects of sodium
valproate on kidney cells have been reported in the liter-
ature (10, 11). On the other hand, numerous effects of
the drug on kidney metabolism, such as increased me-
tabolism of glutamine and increased synthesis of ammo-
nium, significantly decreased renal absorption of lactate
and pyruvate, inhibition of long-chain fatty acid oxida-
tion, decreased synthesis of carnitine in the kidney, inhi-
bition of ketogenesis, mitochondrial dysfunction, etc.,
have been reported (9, 21). All these changes appear to
support the hypothesis that treatment of epilepsy with
sodium valproate might damage kidney cells, depending
on the duration of therapy, dosage and individual
susceptibility.
For the following, we focused our attention on the activ-
ity of enzymes localized on the renal proximal tubule
cells: according to Warter et al. (8), sodium valproate, a
short-chain fatty acid, affects the structure of the cell
membrane; by histologic examination of the renal tissue
from patients with interstitial nephritis due to sodium
valproate, China-Young Lin & Huang Ching (11) found
dense material deposited in the basal membrane of tubu-
lar cells; considerable amounts of sodium valproate are
metabolised in the cells of proximal and distal tubules
of the kidney (22).
The investigated enzymes are known as surface enzymes
or integral constituents of the brush-border membrane
cells of the kidney proximal tubules. Their urinary
excretion is considered to be a useful early indicator of
kidney alterations (13).
The time-dependent and significantly elevated catalytic
activities of the three enzymes in the urine of experi-
mental animals pointed to an adverse action of the drug
on the kidney cells. The catalytic activity of alanine
aminopeptidase was significantly increased as early as
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the first day after sodium valproate administration,
which is consistent with the finding that the enzyme is
readily released from the surface of the cell membrane
(23). A relatively early urinary excretion of alanine
aminopeptidase was also observed by Holmes et al. (24)
in their study of the coordinated release of urinary lyso-
somal and brush-border enzymes following renovascular
surgery. The authors conclude that cell components, in-
cluding enzymes, are affected by transitory pathophysio-
logic changes in the kidney. We postulate that the de-
creased enzyme activity in urine after 10 days of treat-
ment was probably due to a significant change in urine
pH. By urine dialysis, we eliminated the inhibitors of
alanine aminopeptidase and other enzymes. However, it
is known from the literature (25) that enzymatic activity
can be decreased by prolonged urine retention in the
bladder, as well as by urine collection over a prolonged
period of time, as in our experiment (18 h). The use of
sodium valproate is associated with an increased forma-
tion of ammonium ions in the body. Thus, the above
data, and the fact that ammonium ions are known to
inhibit alanine aminopeptidase ((26), appears to invali-
date this enzyme as a diagnostic indicator of adverse
changes in kidney cells during the administration of
this drug.
Although the incorporation of γ-glutamyltransferase into
the cell membrane lipid matrix is, according to the liter-
ature, weaker than that of alkaline phosphatase (23),
marked enzymuria, together with notable polyuria, was
observed concurrently for both enzymes on day 4 to the
drug administration. These results are consistent with
the observations of Jung et al. (27), who found that an
increased water intake, i. e. increased diuresis in normal
subjects, resulted in an increased excretion of soluble
forms of the brush-border membrane enzymes, whereas
the excretion of particulate forms was independent of
diuresis. Therefore, in our future studies with sodium
valproate, it might prove useful to determine both forms
of γ-glutamyltransferase and alkaline phosphatase, or to
express the enzyme catalytic activities in relation to cre-
atinine concentration, which is one of the recommended
ways of expressing urinary enzyme catalytic activities
(25). The observed normalization of urine enzyme activ-
ities after 10 days may reflect the adaptation of renal
cells to the presence of the drug. These changes in the
enzyme catalytic activities are consistent with data ob-
tained in similar studies of renal cell impairment (28).
Most of these studies show an intermittent increase in
urinary enzyme activities, depending on the study dura-
tion or the concentration of the potentially toxic sub-
stance.
Whereas the activity of γ-glutamyltransferase in isolated
renal brush-border membrane vesicles decreased as ex-
pected, the marked increase in the activity of alkaline
phosphatase was probably due to the enhanced synthesis
of enzyme multiple forms in the renal tissue (intestinal-
like and hepatic types) and subsequent excretion in the
urine. Thus, Pfleiderer et al. (29) found an increased
amount of the intestinal-like forms of alkaline phosphat-
ase in the urine from subjects receiving potentially toxic
drugs.
In our experiments with rats, 200 mg/kg body weight
sodium valproate per day appeared to cause transient
changes in renal cell membranes, resulting, over a
period of 10 days, in increased enzymuria of the specific
enzymes, polyuria, and changes in urine pH. Proteinuria,
microhaematuria and histological alterations due to the
use of sodium valproate have also been demonstrated in
humans (11). Thus, the data presented appear to suggest
that the state of renal cells should be monitored during
therapy with sodium valproate. This is especially impor-
tant if it is given over a long period, during which not
only transitory but also more severe damage to the renal
tubular cells can be expected to occur. As urinary en-
zymes are very early indicators of adverse renal cell
changes, the present results indicate that the determina-
tion of urinary catalytic activities of γ-glutamyltransfer-
ase and alkaline phosphatase may be useful for monitor-
ing patients for adverse effects of sodium valproate
treatment.
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